Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 14/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624173 | 0.85 | MLYCD (0.55) | MLYCDCES1MAPTL3MBTL1 | |
| SCHEMBL17853880 | 0.83 | MAPT (0.43) | MAPTFYNL3MBTL1 | |
| SCHEMBL8444552 | 0.82 | PARP10 (0.59) | MLYCDMAPTMAOB | |
| SCHEMBL25846701 | 0.81 | MLYCD (0.57) | MLYCDCES1MAOBL3MBTL1 | |
| SCHEMBL29645006 | 0.80 | MLYCD (0.56) | MLYCDMAPTL3MBTL1 | |
| SCHEMBL9549256 | 0.80 | KMT2A (0.53) | MAPTFYNL3MBTL1 | |
| SCHEMBL1398393 | 0.80 | CES1 (0.59) | MLYCDCES1MAPT | |
| SCHEMBL3798190 | 0.80 | CES2 (0.59) | CES1MAPTFYNL3MBTL1 | |
| SCHEMBL15000339 | 0.79 | TP53 (0.58) | MLYCDL3MBTL1 | |
| SCHEMBL686115 | 0.79 | FYN (0.36) | MAPTFYNMAOBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431280-A1 | ARYL SULFAMATE DERIVATIVES | Kyowa Hakko Kogyo Co., Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | SULT1A1, STS, CYP26A1 | MLYCD 4438/4885CES1 4/4885MAPT 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.